Literature DB >> 12712438

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.

James W F Catto1, George Xinarianos, Julian L Burton, Mark Meuth, Freddie C Hamdy.   

Abstract

Defects in the DNA mismatch repair proteins result in microsatellite instability and malignancy in hereditary non-polyposis colorectal carcinoma (HNPCC). However, the role of mismatch repair (MMR) proteins and microsatellite instability (MSI) in transitional cell carcinoma of the bladder is less clear. In our study, the expression of 2 MMR proteins and the frequency of MSI in Transitional cell carcinoma of the bladder (TCC) were investigated. One hundred eleven patients with TCC of the bladder were studied, with complete clinicopathological data (median follow up of 5 years, range 5-16 years). Immunohistochemistry was used to detect the expression levels of hMLH1 and hMSH2. Microsatellite analysis for 14 loci (10 loci from the Bethesda consensus panel and the repeats in the TGFbetaR2, BAX, hMSH3 and hMSH6 genes) was performed on 84 tumors. Reduced expression of either MMR protein was seen in 26 of 111 tumors (23%). Reduced expression was seen more commonly in muscle invasive (p<0.03) and high grade TCC (p<0.03) than in superficial, low grade tumors. By 5 years, reduced expression of either MMR protein was associated with fewer recurrences of superficial tumors (p=0.015) and fewer relapses in all tumors (p=0.03), compared to tumors with normal expression. Nine tumors had reduced expression of both MMR proteins, analysis which suggests a synergistic reduction in expression (p=0.001). MMR expression was related to patient age, younger patients being more likely to have reduced MMR expression than older patients (p<0.01). MSI was seen at multiple loci in 1 tumor (1%) and at a single locus in 6 tumors (7%). MSI was not associated with MMR expression. Our findings indicate that reduced expression of the MMR proteins may have an important contribution in the development of a subset of TCCs and suggest a potential role for MMR expression as prognostic indicators. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712438     DOI: 10.1002/ijc.11109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.

Authors:  Guillaume Ploussard; Hany Soliman; Francis Dubosq; Paul Méria; Jérôme Vérine; François Desgrand-Champs; Hugues Dethé; Pierre Mongiat-Artus
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

2.  Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer.

Authors:  Francesca Sanguedolce; Antonella Cormio; Paolo Massenio; Maria C Pedicillo; Simona Cagiano; Francesca Fortunato; Beppe Calò; Giuseppe Di Fino; Giuseppe Carrieri; Pantaleo Bufo; Luigi Cormio
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-23       Impact factor: 4.553

3.  A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.

Authors:  Andrew Goodspeed; Annie Jean; James C Costello
Journal:  Eur Urol       Date:  2018-11-07       Impact factor: 20.096

4.  Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.

Authors:  Maximilian Burger; Stefan Denzinger; Christine G Hammerschmied; Andrea Tannapfel; Ellen C Obermann; Wolf F Wieland; Arndt Hartmann; Robert Stoehr
Journal:  J Mol Med (Berl)       Date:  2006-08-03       Impact factor: 4.599

5.  Prevalence and spectrum of microsatellite alterations in nonmuscle invasive bladder cancers.

Authors:  Guillaume Legrand; Hany Soliman; Francis Dubosq; Jérôme Vérine; François Desgrandchamps; Hugues de Thé; Pierre Mongiat-Artus; Guillaume Ploussard
Journal:  Am J Cancer Res       Date:  2011-04-05       Impact factor: 6.166

6.  Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium.

Authors:  Dimitra P Vageli; Stavros Giannopoulos; Sotirios G Doukas; Christos Kalaitzis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; George K Koukoulis; Stavros Touloupidis
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

7.  MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer.

Authors:  Wen-Jing Liu; Yu-Pei Zhao; Tai-Ping Zhang; Li Zhou; Quan-Cai Cui; Wei-Xun Zhou; Lei You; Ge Chen; Hong Shu
Journal:  J Gastrointest Surg       Date:  2013-05-29       Impact factor: 3.452

8.  Identification of Lynch syndrome-associated DNA mismatch repair-deficient bladder cancer in a Japanese hospital-based population.

Authors:  Makoto Kagawa; Satoru Kawakami; Azusa Yamamoto; Okihide Suzuki; Nao Kamae; Hidetaka Eguchi; Yasushi Okazaki; Gou Yamamoto; Kiwamu Akagi; Jun-Ichi Tamaru; Tatsuro Yamaguchi; Tomio Arai; Hideyuki Ishida
Journal:  Int J Clin Oncol       Date:  2021-07-02       Impact factor: 3.402

9.  Molecular subtype classification of urothelial carcinoma in Lynch syndrome.

Authors:  Christina Therkildsen; Pontus Eriksson; Mattias Höglund; Mats Jönsson; Gottfrid Sjödahl; Mef Nilbert; Fredrik Liedberg
Journal:  Mol Oncol       Date:  2018-06-19       Impact factor: 6.603

10.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.